Rekombinanter TCP1 alpha/CCTA Antikörper (full length)

Produktnummer ABIN7879125

Der Kaninchen Monoklonal anti-TCP1 alpha/CCTA Antikörper wird verwendet zum Nachweis von TCP1 alpha/CCTA in Proben von Human, Maus und Ratte. Er wurde validiert für IHC (p).

Kurzübersicht für Rekombinanter TCP1 alpha/CCTA Antikörper (full length) (ABIN7879125)

Target: TCP1 alpha/CCTA (TCP1) (T-Complex 1 (TCP1))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser TCP1 alpha/CCTA Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Güteklasse: Carrier-free

Klon: TP63-1423R

Produktdetails anti-TCP1 alpha/CCTA Antikörper

Bindungsspezifität: full length

Verwendungszweck: Recombinant p63 Antibody / Rabbit Monoclonal (azide and preservative free)

Aufreinigung: Protein A affinity chromatography

Immunogen: Full-length human recombinant protein was used as the immunogen for the recombinant p63 antibody.

Isotyp: IgG, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the recombinant p63 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store the recombinant p63 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Details zu TCP1 alpha/CCTA

Target: TCP1 alpha/CCTA (TCP1) (T-Complex 1 (TCP1))

Andere Bezeichnung: p63

Hintergrund: P63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands, however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90 % . Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80 %. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

UniProt: Q9H3D4